Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Sebban

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Haematologica|May 7, 2013
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphomaEmmanuel Bachy, Roch Houot, Franck Morschhauser, et al.
Hematological Oncology|March 8, 2011
Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case seriesSawyna Provencher, Céline Ferlay, Khaoula Alaoui-Slimani, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2012
CD4 lymphopenia to identify end-of-life metastatic cancer patientsJulien Péron, Claire Cropet, Olivier Tredan, et al.
Blood|October 6, 2021
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trialsCarla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, et al.
Journal of Adolescent and Young Adult Oncology|August 15, 2019
Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes RegionArthur Dony, Amine Belhabri, Yves Bertrand, et al.
Blood|October 22, 2010
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?Hervé Avet-Loiseau, Florent Malard, Loic Campion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Cancer Research|June 25, 2009
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomasIsabelle Ray-Coquard, Claire Cropet, Martine Van Glabbeke, et al.
Cancer|March 23, 2019
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional studyNicolas Mounier, Sabine Anthony, Raphaël Busson, et al.
Bulletin Du Cancer|February 19, 2017
[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment]Sabine Anthony, Pierre Hebel, André Garrel, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Haematologica|May 7, 2013
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphomaEmmanuel Bachy, Roch Houot, Franck Morschhauser, et al.
Hematological Oncology|March 8, 2011
Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case seriesSawyna Provencher, Céline Ferlay, Khaoula Alaoui-Slimani, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2012
CD4 lymphopenia to identify end-of-life metastatic cancer patientsJulien Péron, Claire Cropet, Olivier Tredan, et al.
Blood|October 6, 2021
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trialsCarla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, et al.
Journal of Adolescent and Young Adult Oncology|August 15, 2019
Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes RegionArthur Dony, Amine Belhabri, Yves Bertrand, et al.
Blood|October 22, 2010
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?Hervé Avet-Loiseau, Florent Malard, Loic Campion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Cancer Research|June 25, 2009
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomasIsabelle Ray-Coquard, Claire Cropet, Martine Van Glabbeke, et al.
Cancer|March 23, 2019
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional studyNicolas Mounier, Sabine Anthony, Raphaël Busson, et al.
Bulletin Du Cancer|February 19, 2017
[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment]Sabine Anthony, Pierre Hebel, André Garrel, et al.
Pageof 6